Patients experienced TEAEs leading to temporary interruption of pembrolizumab (3 [15.8%]), including 1 (5.3%) patient each with thyroiditis, increased ALT, and increased blood bilirubin; EVER4010001 (4 [21.0%]), where reasons for dose interruption were not confined to a single/small group of PTs; and EVER4010001 and pembrolizumab (2 [10.5%]). This evidence concerns the gene GPT and thyroid gland disorder.